Anaptysbio (ANAB) EBT (2016 - 2026)
Anaptysbio (ANAB) reported EBT of -$52.8 million for Q1 2026, down 34.51% on a YoY basis from -$80.7 million in Q1 2025, and down 184.2% quarter-over-quarter from $62.8 million in Q4 2025.
Anaptysbio (ANAB) EBT (2016 - 2026) Analysis & Trends
Anaptysbio has reported EBT for 11 years, with the latest figure at -$52.8 million in Q1 2026.
- For the quarter ending Q1 2026, EBT fell 34.51% year-over-year to -$52.8 million; the trailing twelve-month figure through Mar 2026 stood at -$13.6 million (up 90.36% YoY), and the FY2024 full-year result was -$145.4 million, down 337962.79% from the prior year.
- EBT for Q1 2026 stood at -$52.8 million, down from $62.8 million in the prior quarter.
- The five-year high for EBT was $121.4 million in Q4 2023, with the low at -$52.8 million in Q1 2026.
- Historically, EBT has averaged -$17.7 million across 5 years, with a median of -$32.9 million in 2024.
- Annual changes were most pronounced in 2022 — EBT sank 6121.91% — and 2023, when it surged 648.32%.
- Anaptysbio's EBT stood at -$22.1 million in 2022, then surged by 648.32% to $121.4 million in 2023, then slumped by 118.07% to -$21.9 million in 2024, then soared by 386.21% to $62.8 million in 2025, then sank by 184.2% to -$52.8 million in 2026.
- The last three EBT figures came in at -$52.8 million (Q1 2026), $62.8 million (Q4 2025), and $15.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 19.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.18 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.31 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Anaptysbio | 1.66 Bn | 1.38 Bn | - | -52.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.84 Mn |
| Dec 31, 2025 | 62.76 Mn |
| Sep 30, 2025 | 15.11 Mn |
| Jun 30, 2025 | -38.59 Mn |
| Mar 31, 2025 | -39.29 Mn |
| Dec 31, 2024 | -21.93 Mn |
| Sep 30, 2024 | -32.85 Mn |
| Jun 30, 2024 | -46.65 Mn |
| Mar 31, 2024 | -43.94 Mn |
| Dec 31, 2023 | 121.37 Mn |
| Sep 30, 2023 | -37.31 Mn |
| Jun 30, 2023 | -39.85 Mn |
| Mar 31, 2023 | -39.92 Mn |
| Dec 31, 2022 | -22.13 Mn |
| Sep 30, 2022 | -27.37 Mn |
| Jun 30, 2022 | -26.69 Mn |
| Mar 31, 2022 | -31.41 Mn |
| Dec 31, 2021 | -31.09 Mn |
| Sep 30, 2021 | -6.70 Mn |
| Jun 30, 2021 | -429,000.00 |